Navigation Links
Actavis and Warner Chilcott Announce Effectiveness of Registration Statement on Form S-4
Date:7/31/2013

e intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by Warner Chilcott's management that, although Warner Chilcott believes to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by Warner Chilcott's forward-looking statements: the timing to consummate the proposed transaction with Actavis; the risk that a condition to closing of the proposed transaction with Actavis may not be satisfied; the risk that a regulatory approval that may be required for the proposed transaction with Actavis is delayed, is not obtained or is obtained subject to conditions that are not anticipated; New Actavis' ability to achieve the synergies and value creation contemplated by the proposed acquisition; New Actavis' ability to promptly and effectively integrate Actavis' and Warner Chilcott's businesses; the diversion of management time on transaction-related issues; Warner Chilcott's substantial indebtedness, including increases in the LIBOR rates on its variable-rate indebtedness above the applicable floor amounts; competitive factors and market conditions in the industry in which Warner Chilcott operates, including the approval and introduction of generic or branded products that compete with Warner Chilcott's products; Warner Chilcott's ability to protect its intellectual property; a delay in qualifying any of Warner Chilcott's manufacturing facilities that produce its products, production or regulatory problems with either its own manufacturing facilities or those of third party manufacturers, packagers or API suppliers upon whom it may rely for some of its products or other disruptions wi
'/>"/>
SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
10. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
11. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional ... Toronto -based 3D visualization leader ... Congress of Neurological Surgeons Annual Meeting that they ... for brain surgery. The collaboration is the first ... combination to improve patient outcomes. NICO,s BrainPath® interventional ...
(Date:10/20/2014)... 20, 2014   BioNano Genomics announced today achievement ... to collect human data at 30X depth, sufficient for a ... new capability was established and demonstrated for the IrysChip TM ... System and will be rolled out to BioNano,s ... be showcasing this advancement at the American Society for ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... Site Solutions Summit, an annual conference of premier clinical ... their 2010 Site Solutions Summit Eagle Awards to Eli ... PPD, Inc., as the top contract research organization (CRO). ... CRO for their commitment to outstanding leadership, professionalism, integrity, ...
... Cardiogenesis Corporation (OTCQB: CGCP) announced that the company will ... 2010 on Wednesday, November 3, 2010.  The company added ... R. Abbott, its Senior Vice President and Chief Financial ... at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) ...
Cached Medicine Technology:Eli Lilly and Company and PPD, Inc., Honored for Building Strong Clinical Research Site Partnerships at the Site Solutions Summit Annual Meeting 2Eli Lilly and Company and PPD, Inc., Honored for Building Strong Clinical Research Site Partnerships at the Site Solutions Summit Annual Meeting 3Eli Lilly and Company and PPD, Inc., Honored for Building Strong Clinical Research Site Partnerships at the Site Solutions Summit Annual Meeting 4Cardiogenesis Corporation to Report 2010 Third Quarter Results on November 3rd 2
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Two sisters in high ... damage. Ilina and Medha Krishen use electronic stethoscopes, ... of trouble in breathing patterns or heartbeats. Ilina, ... Michigan, wanted to find a way to detect early ... Using an electronic stethoscope, Ilina recorded one breath cycle ...
(Date:10/22/2014)... By Dennis Thompson ... -- U.S. health officials on Monday officially tightened guidelines for ... with no skin exposure and use of a respirator at ... Prevention decided to issue the tougher rules after two Dallas ... diagnosed in the United States, Liberian national Thomas Eric Duncan. ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 Allegheny ... minimally-invasive procedure that enables physicians to repair a damaged ... The MitraClip system, developed by Abbott ... (MR), a progressive and life-threatening condition in which the ... blood to flow backward from the heart’s left ventricle ...
(Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... -- The growing number of people with Alzheimer,s disease in ... a responsibility that health experts warn can pose risks to ... to protect their health, says Rebecca Axline, a clinical social ... To keep stress in check, for instance, she emphasizes the ...
... HealthDay Reporter , WEDNESDAY, April 27 (HealthDay News) -- ... sugar control, often sending people with type 2 diabetes ... that happens. Now, a new study provides some ... decline dramatically in those who have the bypass surgery, ...
... brainy bookworms unprepared for the rough and tumble of post-graduation ... tend to fade away quickly when injected into cancer patients. ... can cause such cells to survive in patients, bloodstreams for ... of other, highly toxic treatments, a new study shows. ...
... Researchers in New York City say they are the first ... cells. A team at Albert Einstein College of Medicine ... gene transcription in living yeast cells, they say. Transcription occurs ... messenger RNA (mRNA) that then make the protein coded by ...
... , WEDNESDAY, April 27 (HealthDay News) -- An ... than earlier medications will be reviewed Thursday by a panel ... Telaprevir, made by Vertex Pharmaceuticals of Cambridge, Mass., would be ... levels of the virus, which can cause severe liver damage, ...
... (ASTRO) has developed a guideline for the use of ... to palliate thoracic symptoms caused by advanced lung cancer. ... Oncology , an official journal of ASTRO. Many patients ... treat symptoms related to cancer, such as cough, shortness ...
Cached Medicine News:Health News:Alzheimer's Caregivers Need Care, Too 2Health News:New Clues to How Gastric Bypass Surgery Combats Diabetes 2Health News:New Clues to How Gastric Bypass Surgery Combats Diabetes 3Health News:New technique extends cancer-fighting cells' potency in melanoma patients 2Health News:New technique extends cancer-fighting cells' potency in melanoma patients 3Health News:New technique extends cancer-fighting cells' potency in melanoma patients 4Health News:Researchers Describe Gene Activity in Living Cells 2Health News:Novel Hepatitis C Drug Holds Promise: FDA 2Health News:ASTRO publishes evidence-based guideline for thoracic radiotherapy 2
... helps protect you against needlestick injury. Its ... exposure to a contaminated needle, provides easy ... for use in high-risk environments. The one-handed ... for activation of the safety mechanism while ...
... The Omni-Flex System provides the ... in the middle of surgery ... on the incision. The system ... be stable for large patients ...
... The genuine BOOKWALTER™ Retractor System ... fixed" retractor design available. Its wide ... surgical specialites with a versatile system ... field. Individual BOOKWALTER™ Kits are available ...
... the Alexis Wound Retractor provides circumferential ... contamination. For open surgery, the Alexis ... the incision size. For laparoscopic surgery, ... offering retraction and protection when an ...
Medicine Products: